$ImmunityBio, Inc.(IBRX)$ I closed the last 100 positions I had open. Will buy the next dip.
closed further positions on IBRX! The gift that keeps on giving!
Cheers IBRX! Hopefully some of you Tigers 🐅🐅🐅 followed me in these trades for huge profits! Swimming in the 💰💰💰💸💸💸🤑🤑🤑 today! still further upside but it hit my initial target 🎯. Please follow me for further profitable short-term trades❣️
ImmunityBio Company Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
ImmunityBio NASDAQ:IBRX - last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03). The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.53 million. On average, equities research analysts expect that ImmunityBio, Inc. will post -0.86 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ImmunityBio
A number of hedge funds and other institutional investors have recently made changes to their positions in IBRX. Bleakley Financial Group LLC bought a new position in ImmunityBio during the 1st quarter worth approximately $58,000. Lazard Asset Management LLC raised its stake in ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company's stock worth $68,000 after buying an additional 6,593 shares during the last quarter. Axxcess Wealth Management LLC bought a new position in ImmunityBio during the first quarter worth $85,000. Algert Global LLC bought a new stake in ImmunityBio during the second quarter valued at $86,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after acquiring an additional 4,545 shares during the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.
Happy trading ahead, BC! 🍀
@Tiger_comments @TigerPicks @TigerObserver @TigerStars @Daily_Discussion @TigerPM @TigerGPT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Earnings Data:
The latest reported earnings period for ImmunityBio, Inc. (IBRX) was in 2024Q2, with a report date of August 12, 2024.
The company reported an earnings per share of -$0.20 for the quarter, missing analysts' consensus estimates of -$0.17 by -$0.03.
The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.53 million.
For the accumulated earnings results, the company reported an earnings per share of -$0.40 for the first half of 2024.
The net assets per share for the first half of 2024 were -$1.01.
The financials net profit for the first half of 2024 was -$268.71 million.
Earnings Forecast:
The earnings forecast for the upcoming quarter, 2024Q3, is an estimated earnings per share of -$0.18.
The forecasted gross income for 2024Q3 is $2.93 million, and the forecasted EBIT is -$93.97 million.
The accumulated earnings forecast for the fiscal year 2024 (FY) is an estimated earnings per share of -$0.82.
The forecasted gross income for 2024FY is $10.14 million, and the forecasted EBIT is -$386.70 million.
Please note that the earnings data provided is for reference only and should not be considered as investment advice.
Click here to read an article providing an analysis of ImmunityBio's earnings and potential upside.
Click here to read an article about the initiation of dosing in a Phase 1 study for ImmunityBio's potential non-Hodgkin's lymphoma treatment.
Click here to read an article about BioNTech's upcoming earnings report, which may have implications for the biotechnology sector.
Click here to read an article about positive trial updates for ImmunityBio's cancer treatment.
Please note that the above analysis is for reference only and should not be considered as investment advice.